Denali Therapeutics Inc. DNLI Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s financing cash flow?
- Denali Therapeutics Inc. (DNLI) reported financing cash flow of $219.04M in Q1 2026.
- How has Denali Therapeutics Inc.'s financing cash flow changed year-over-year?
- Denali Therapeutics Inc.'s financing cash flow increased by 5922.5% year-over-year, from -$3.76M to $219.04M.
- What is the long-term trend for Denali Therapeutics Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Denali Therapeutics Inc.'s financing cash flow has grown at a 113.8% compound annual growth rate (CAGR), from $19.35M to $189.22M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.